REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.
A live audio webcast and replay of the fireside chat will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. An NDA for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS) is currently under review by the FDA and was granted Priority Review. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
hygh-tec Odor Solution™ will be launched in Q2 2025FDA clearance and MDR certification already securedFirst generation…
46% Plan to Leave Their Organizations in the Next 12 MonthsDALLAS, March 24, 2025 (GLOBE…
TORONTO, March 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…
BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered pathology, is…
Company prioritizes ophthalmology pipeline programs with potential to provide new or improved treatment options in…
The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
